

thyroiditis, type I diabetes, ulcerative colitis, uveitis, vitiligo, vasculitis, and Wegener's granulomatosis.

In another aspect, there is provided the use of a compound of formula (I) as disclosed herein or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a disease or condition in a subject in need thereof, wherein said disease or condition is selected from the group consisting of: diabetic nephropathy, hypertensive nephropathy, HIV-associated nephropathy, glomerulonephritis, lupus nephritis, IgA nephropathy, focal segmental glomerulosclerosis, membranous glomerulonephritis, minimal change disease, polycystic kidney disease and tubular interstitial nephritis.

In another aspect, there is provided the use of a compound of formula (I) as disclosed herein or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating an acute kidney disease or condition in a subject in need thereof, wherein said acute kidney disease or condition is selected from the group consisting of: ischemia-reperfusion induced, cardiac and major surgery induced, percutaneous coronary intervention induced, radio-contrast agent induced, sepsis induced, pneumonia induced, and drug toxicity induced.

In another aspect, there is provided the use of a compound of formula (I) as disclosed herein or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating an acquired immunodeficiency syndrome (AIDS) in a subject.

In another aspect, there is provided the use of a compound of formula (I) as disclosed herein or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a disease or condition in a subject, wherein said disease or condition is selected from the group consisting of: obesity, dyslipidemia, hypercholesterolemia, Alzheimer's disease, metabolic syndrome, hepatic steatosis, type II diabetes, insulin resistance, diabetic retinopathy and diabetic neuropathy.

In another aspect, there is provided the use of a compound of formula (I) as disclosed herein or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for contraception in a male subject.

In another aspect, there is provided a method of contraception in a male subject comprising administering a therapeutically effective amount of a compound of formula (I) as disclosed herein or a pharmaceutically acceptable salt thereof, to a male subject in need thereof.

Pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt, alone or in combination with a second active pharmaceutical agent, are also provided.

DETAILED DESCRIPTION

Disclosed herein are compounds of formula (I)

condition is selected from the group consisting of: diabetic nephropathy, hypertensive nephropathy, HIV-associated nephropathy, glomerulonephritis, lupus nephritis, IgA nephropathy, focal segmental glomerulosclerosis, membranous glomerulonephritis, minimal change disease, polycystic kidney disease and tubular interstitial nephritis.

61. Use of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating an acute kidney disease or condition in a subject in need thereof, wherein said acute kidney disease or condition is selected from the group consisting of: ischemia-reperfusion induced, cardiac and major surgery induced, percutaneous coronary intervention induced, radio-contrast agent induced, sepsis induced, pneumonia induced, and drug toxicity induced.

62. Use of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating an acquired immunodeficiency syndrome (AIDS) in a subject.

63. Use of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a disease or condition in a subject, wherein said disease or condition is selected from the group consisting of: obesity, dyslipidemia, hypercholesterolemia, Alzheimer's disease, metabolic syndrome, hepatic steatosis, type II diabetes, insulin resistance, diabetic retinopathy and diabetic neuropathy.

64. ~~Use of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable acceptable salt thereof, in the manufacture of a medicament for~~ A method of contraception in a male subject comprising administering a therapeutically effective amount of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, to a male subject in need thereof.